TACE is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Second Affiliated Hospital of Guangzhou Medical University (1), Jiangsu HengRui Medicine Co., Ltd. (1) and Tongji Hospital (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma; HCC.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC Hepatocellular Carcinoma Non-resectable |
Phase 3 | Recruiting |
| NCT07154082 | Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma (HCC) |
Phase 2 | Recruiting |
| NCT07350070 | TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension (ClinicalTrials.gov ↗) HCC, Liver Cirrhosis, Portal Hypertension |
Phase 2 | Not yet open |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Hepatocellular Carcinoma Non-resectable | 1 |
| Hepatocellular Carcinoma | 1 |
| HCC | 1 |
| Liver Cirrhosis | 1 |
| Portal Hypertension | 1 |
| Hepatocellular Carcinoma (HCC) | 1 |
| Lead sponsor | Trials |
|---|---|
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Tongji Hospital | 1 |
| Wei Zhang | 1 |
| Register | TACE trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TACE works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TACE (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.